MRNA: Moderna, Inc. - Summary | Jitta

Moderna, Inc.

NASDAQ:MRNA

Price
$147.44
Loss Chance
47.2%
3.03JITTA SCORE
18.50%Over Jitta Line
Jitta Ranking
210 / 592
602 / 1,180
3,802 / 5,029
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (26)
Recent Business Performance (31)
Financial Strength (73)
Return to Shareholders (37)
Competitive Advantage (45)
Jitta Signs
Debt LevelLow Long Term Debt
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2020
Operating MarginDeclined
Recent Business PerformanceEarning decline 67.38% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
3.03
18.50%
1.26
110.87%
1.96
187.51%
Biotechnology
6.93
104.45%
4.87
82.01%
5.55
39.22%
COMPANY DESCRIPTION
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.